Zurampic (lesinurad) is a drug to treat high levels of uric acid in the blood (hyperuricemia) associated with gout disease.
About Gout
High levels of uric acid in blood and recurring attacks of joint inflammation are the main symptoms of gout. Lifestyle changes like weight loss, increasing fluid intake and dietary changes can help.
High levels of uric acid in blood and recurring attacks of joint inflammation are the main symptoms of gout. Lifestyle changes like weight loss, increasing fluid intake and dietary changes can help.
‘Zurampic gained FDA approval in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia (high levels of uric acid in the blood) associated with gout.’
"Controlling hyperuricemia is critical to the long-term treatment of gout. Zurampic provides a new treatment option for the millions of people who may develop gout over their lifetimes,” said Dr.Badrul Chowdhury, director of the Division of Pulmonary, Allergy and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research. Zurampic works by helping the kidney excrete uric acid. It does this by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney.
FDA has approved the drug with a box warning as it has a risk of acute kidney (renal) failure, which is more common when used without an XOI and with higher than approved doses of Zurampic.
AstraZeneca Collaborates With Wallenberg for Developing Secretome Therapeutics
London-based drug firm has entered into a new field of developing drugs using proteins secreted by the cells called as “Secretome”.
London-based drug firm has entered into a new field of developing drugs using proteins secreted by the cells called as “Secretome”.
GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus
GSK’s phase III trials of the B-lymphocyte stimulator reduced disease activity by 61% and AZ’s phase II trials of anifrolumab reduced the activity by 51.5%.
GSK’s phase III trials of the B-lymphocyte stimulator reduced disease activity by 61% and AZ’s phase II trials of anifrolumab reduced the activity by 51.5%.
In People With Hyperuricemia Study Explores Impact of Urate-Lowering Therapy on Kidney Disease
New study finds that urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia.
New study finds that urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia.
